Auriga Reiterates Buy, $20 Target on Omnicell

Auriga maintains its Buy rating and $20 target on Omnicell, Inc. OMCL as the company's entrance into China hold potential. Auriga says, “We are reiterating our BUY rating on Omnicell on the heels of its announcement of its first installation in China with Peking Union Medical College Hospital (PUMCH). The addressable market in China for cabinet automation is roughly $200 million, and the PUMCH contract and distributor relationship with China Resources Beijing Pharmaceutical Company presents a huge foot in the door. We are not changing FY12 estimates at this point but believe there could be upside to our model depending on the rate of China adoption.” OMCL closed at $14.68 per share on Monday, up 4.34 percent.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorReiterationPre-Market OutlookAnalyst RatingsAuriga
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!